Two COVID-19 vaccines from Sinopharm in China have shown more than 70% effectiveness against symptomatic cases, but it is still unclear what protection they offer against severe or asymptomatic cases, according to the first detailed result of a large study advanced stage released to the public. .
A vaccine developed by a Wuhan-based subsidiary of Sinopharm was 72.8% effective against symptomatic COVID-19 at least two weeks after the second injection, based on interim results, the peer-reviewed study showed Wednesday in the Journal of the American Medical Association. .
This is slightly better than the rate of 72.5% announced in a company statement in February.
Another vaccine developed by a Beijing-based institute linked to Sinopharm, which obtained emergency use approval by the World Health Organization (WHO) this month, showed an efficacy of 78.1 %, according to the newspaper.
The readings were based on calculations from 142 symptomatic cases in a trial involving more than 40,000 participants, 26 who received the vaccine from the Wuhan unit and 21 received the vaccine from the Beijing unit, he said.
“There were only 2 severe cases of COVID-19 among the participants, so conclusions on prevention of severe cases cannot be drawn,” the newspaper said.
“The study could not address the question of whether … vaccines prevent against asymptomatic infection, which requires formal study-wide monitoring via virological and serological tests,” he said. -he declares.
The trial, conducted in countries like the United Arab Emirates and Bahrain, did not recruit pregnant women and people under the age of 18, despite insufficient data for the elderly and those with chronic illnesses. , researchers said.
Data from other trials in Egypt and Jordan will be included in the final analysis, the researchers said.
Our Standards: Thomson Reuters Trust Principles.